News

Current vaccines to prevent COVID-19 are highly effective in producing antibodies in pregnant people, resulting in more antibodies than what is generated from a natural SARS-CoV-2 virus infection, according to a study funded by the National Institutes of Health. Moreover, antibodies produced after vaccination are present in breastmilk and travel across the placenta, indicating that vaccination during pregnancy will also confer immunity to newborns.

For many COVID-19 patients, full recovery remains elusive even long after they should feel “better.” NIH recently announced research opportunities to understand COVID-19 long haulers, who have what researchers now refer to as Post-acute sequelae of SARS-CoV-2 infection (PASC). NICHD joins these opportunities while remaining focused on PASC patients within our audiences of interest—pregnant and lactating people, children, and those with disabilities.

A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.

Pregnant people need to be protected through research rather than from research, the authors contend.

As the COVID-19 pandemic persists, SARS-CoV-2 vaccines offer the potential to halt the spread of the virus. Yet, we know very little about the effectiveness and safety of the vaccines during pregnancy.

NIH-funded study suggests mother-to-infant transmission appears to be rare

Increased stress may interfere with adjustment to new motherhood, mother-infant bonding

2020 was a year filled with many challenges. NICHD remained focused on our core mission, advancing key research in women’s health, reproductive science, rare childhood diseases and many more. Watch the video below and review our research highlights of 2020.

Read about NICHD’s research findings and activities from 2020.

For pregnant women with COVID-19 in the third trimester, antibodies against the SARS-CoV-2 virus appear to be transferred to the fetus at lower levels, compared to antibodies against two other respiratory diseases, suggests a study funded by the National Institutes of Health. However, one type of antibody against SARS-CoV-2 was transferred to the fetus more efficiently than the other antibodies against the virus, raising the possibility of at least some immune protection against the disease for the newborn.

Pregnant women who are infected with SARS-CoV-2, the virus that causes COVID-19, during the third trimester are unlikely to pass the infection to their newborns, suggests an NIH-funded study.

The study of approximately 16,000 pregnant women will continue 12 months after childbirth and compare maternal, fetal and newborn outcomes of participants infected with the virus to those of pregnant women who have not.

The placental membranes that contain the fetus and amniotic fluid lack the messenger RNA (mRNA) molecule required to manufacture the ACE2 receptor, the main cell surface receptor used by the SARS-CoV-2 virus to cause infection, according to a study by researchers at the National Institutes of Health.

As the nation begins to return to work and businesses re-open, reliable COVID-19 testing is needed. NIH is rising to the challenge.

Crisis often brings out the best in us. Recognizing one of NICHD’s essential workers on the front lines of the response to COVID-19 in New Mexico’s Navajo Nation.

Researchers to evaluate medical records of 21,000 pregnant women